William DuVal

Cooley advised Luna Innovations, a global leader in advanced fiber optic-based technology, on its $50 million investment from White Hat Capital Partners and its acquisition of Silixa.

Cooley advised Cardlytics, an advertising platform in banks’ digital channels, on its cooperation agreement with CAS Investment Partners, a 14.4% stockholder of Cardlytics.

Cooley advised the underwriters on Nanobiotix’s $113.3 million initial public offering of 8,395,000 ordinary shares (global offering) – including the offering of 6,540,000 American depositary shares, each representing one ordinary share, in the US (the US offering) and a concurrent offering of 1,855,000 ordinary shares in certain jurisdictions outside of the US to certain investors (the European offering) – which includes the full exercise of the underwriters’ option to purchase additional shares. Jefferies acted as global coordinator and joint book-running manager for the global offering; Evercore Group and UBS Securities acted as joint book-running managers for the US offering; and Gilbert Dupont acted as manager for the European offering. Nanobiotix, whose securities now trade on the Nasdaq Global Select Market under the symbol NBTX, also trades on the Euronext Paris Market under the symbol NANO. Nanobiotix is a clinical-stage nanomedicine company pioneering new approaches to the treatment of cancers. Partners Brian Leaf, Div Gupta and David Boles led the Cooley team.

Cooley advised Autolus Therapeutics on its $172.5 million initial public offering of 10,147,059 American Depositary Shares, which includes the full exercise of the underwriters’ option to purchase additional shares.